BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 25638704)

  • 1. Efficacy and toxicity of sunitinib for non clear cell renal cell carcinoma (RCC): a systematic review of the literature.
    Abdel-Rahman O; Fouad M
    Crit Rev Oncol Hematol; 2015 May; 94(2):238-50. PubMed ID: 25638704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial.
    Tannir NM; Jonasch E; Albiges L; Altinmakas E; Ng CS; Matin SF; Wang X; Qiao W; Dubauskas Lim Z; Tamboli P; Rao P; Sircar K; Karam JA; McDermott DF; Wood CG; Choueiri TK
    Eur Urol; 2016 May; 69(5):866-74. PubMed ID: 26626617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sunitinib in patients with metastatic renal cell carcinoma: Birmingham experience.
    Ansari J; Fatima A; Fernando K; Collins S; James ND; Porfiri E
    Oncol Rep; 2010 Aug; 24(2):507-10. PubMed ID: 20596640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French Genitourinary Group (GETUG)†.
    Ravaud A; Oudard S; De Fromont M; Chevreau C; Gravis G; Zanetta S; Theodore C; Jimenez M; Sevin E; Laguerre B; Rolland F; Ouali M; Culine S; Escudier B
    Ann Oncol; 2015 Jun; 26(6):1123-1128. PubMed ID: 25802238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sunitinib for patients with metastatic non-clear cell renal cell carcinoma: a Multicenter Retrospective Turkish Oncology Group trial.
    Yildiz I; Ekenel M; Akman T; Kocar M; Uysal M; Kanitez M; Varol U; Bayoglu IV; Tural D; Kaplan MA; Avci N; Sürmeli Z; Dede İ; Ulaş A; Yazici O; Basaran M
    Anticancer Res; 2014 Aug; 34(8):4329-34. PubMed ID: 25075067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma.
    Molina AM; Feldman DR; Ginsberg MS; Kroog G; Tickoo SK; Jia X; Georges M; Patil S; Baum MS; Reuter VE; Motzer RJ
    Invest New Drugs; 2012 Feb; 30(1):335-40. PubMed ID: 20711632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sunitinib in metastatic renal cell carcinoma: Experience from single center study, efficacy and safety.
    Patel KB; Panchal HP; Karanwal AB; Parekh BB; Shah S; Prasad S
    Indian J Cancer; 2016; 53(1):118-22. PubMed ID: 27146758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcome of Patients With Metastatic Chromophobe Renal Cell Carcinoma Treated With Sunitinib.
    Keizman D; Sarid D; Lee JL; Sella A; Gottfried M; Hammers H; Eisenberger MA; Carducci MA; Sinibaldi V; Neiman V; Rosenbaum E; Peer A; Neumann A; Mermershtain W; Rouvinov K; Berger R; Yildiz I
    Oncologist; 2016 Oct; 21(10):1212-1217. PubMed ID: 27382030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of sunitinib for advanced non-clear cell renal cell carcinoma.
    Shi HZ; Tian J; Li CL
    Asia Pac J Clin Oncol; 2015 Dec; 11(4):328-33. PubMed ID: 26471774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors.
    Adams VR; Leggas M
    Clin Ther; 2007 Jul; 29(7):1338-53. PubMed ID: 17825686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial.
    Gore ME; Szczylik C; Porta C; Bracarda S; Bjarnason GA; Oudard S; Hariharan S; Lee SH; Haanen J; Castellano D; Vrdoljak E; Schöffski P; Mainwaring P; Nieto A; Yuan J; Bukowski R
    Lancet Oncol; 2009 Aug; 10(8):757-63. PubMed ID: 19615940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and Economic Outcomes in Elderly Advanced Renal Cell Carcinoma Patients Starting Pazopanib or Sunitinib Treatment: A Retrospective Medicare Claims Analysis.
    Vogelzang NJ; Pal SK; Ghate SR; Swallow E; Li N; Peeples M; Zichlin ML; Meiselbach MK; Perez JR; Agarwal N
    Adv Ther; 2017 Nov; 34(11):2452-2465. PubMed ID: 29076108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II trial of sunitinib in patients with renal cell cancer and untreated brain metastases.
    Chevreau C; Ravaud A; Escudier B; Amela E; Delva R; Rolland F; Tosi D; Oudard S; Blanc E; Ferlay C; Négrier S;
    Clin Genitourin Cancer; 2014 Feb; 12(1):50-4. PubMed ID: 24268852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Experience with Sunitinib in metastatic renal cell carcinoma (mRCC) patients: pooled analysis from 3 Spanish observational prospective studies.
    Castellano D; Maroto JP; Espinosa E; Grande E; Bolós MV; Llinares J; Esteban E; González Del Alba A; Climent MA; Arranz JA; Méndez MJ; Fernández Parra E; Antón-Aparicio L; Bayona C; Gallegos I; Gallardo E; Samaniego L; García Donas J
    Expert Opin Drug Saf; 2018 Jun; 17(6):573-579. PubMed ID: 28535693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
    Cai W; Yuan YC; Li MY; Kong W; Dong BJ; Chen YH; Zhang J; Xue W; Huang YR; Zhou LX; Huang JW
    Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):384-389. PubMed ID: 29860767
    [No Abstract]   [Full Text] [Related]  

  • 16. Sorafenib or sunitinib as postoperative adjuvant therapy for Chinese patients with locally advanced clear cell renal cell carcinoma at high risk for disease recurrence.
    Zhao J; Zhu Y; Zhang C; Wang X; He H; Wang H; Wu Y; Zhou W; Shen Z
    Urol Oncol; 2013 Nov; 31(8):1800-5. PubMed ID: 22658883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma.
    Tannir NM; Plimack E; Ng C; Tamboli P; Bekele NB; Xiao L; Smith L; Lim Z; Pagliaro L; Araujo J; Aparicio A; Matin S; Wood CG; Jonasch E
    Eur Urol; 2012 Dec; 62(6):1013-9. PubMed ID: 22771265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment patterns and clinical outcomes in patients with renal cell carcinoma in the UK: insights from the RECCORD registry.
    Wagstaff J; Jones R; Hawkins R; Porfiri E; Pickering L; Bahl A; Brown J; Buchan S
    Ann Oncol; 2016 Jan; 27(1):159-65. PubMed ID: 26489444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results.
    Motzer RJ; Ravaud A; Patard JJ; Pandha HS; George DJ; Patel A; Chang YH; Escudier B; Donskov F; Magheli A; Carteni G; Laguerre B; Tomczak P; Breza J; Gerletti P; Lechuga M; Lin X; Casey M; Serfass L; Pantuck AJ; Staehler M
    Eur Urol; 2018 Jan; 73(1):62-68. PubMed ID: 28967554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I/II study of lenalidomide in combination with sunitinib in patients with advanced or metastatic renal cell carcinoma.
    Rini B; Redman B; Garcia JA; Burris HA; Li S; Fandi A; Beck R; Jungnelius U; Infante JR
    Ann Oncol; 2014 Sep; 25(9):1794-1799. PubMed ID: 24914044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.